{"id":"https://openalex.org/W2947385336","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.tps8574","title":"Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy for newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) in a phase III study (RATIONALE 001).","display_name":"Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy for newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) in a phase III study (RATIONALE 001).","publication_year":2019,"publication_date":"2019-05-20","ids":{"openalex":"https://openalex.org/W2947385336","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.tps8574","mag":"2947385336"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2019.37.15_suppl.tps8574","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.tps8574","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.tps8574","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052765751","display_name":"Luis G Paz-Ares","orcid":"https://orcid.org/0000-0002-1947-3364","observed_orcids":["https://orcid.org/0000-0002-1947-3364"]},"institutions":[{"id":"https://openalex.org/I4210101691","display_name":"Hospital Universitario 12 De Octubre","ror":"https://ror.org/00qyh5r35","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210101691","https://openalex.org/I4210139293"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Luis G. Paz-Ares","raw_affiliation_strings":["Hospital Universitario 12 de Octubre, CiberOnc, Universidad Complutense and CNIO, Madrid, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitario 12 de Octubre, CiberOnc, Universidad Complutense and CNIO, Madrid, Spain;","institution_ids":["https://openalex.org/I4210101691"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077453712","display_name":"Suresh Senan","orcid":"https://orcid.org/0000-0003-3995-2204","observed_orcids":["https://orcid.org/0000-0003-3995-2204"]},"institutions":[{"id":"https://openalex.org/I4210151833","display_name":"Amsterdam University Medical Centers","ror":"https://ror.org/05grdyy37","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210151833"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Suresh Senan","raw_affiliation_strings":["Amsterdam University Medical Center, Amsterdam, Netherlands;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amsterdam University Medical Center, Amsterdam, Netherlands;","institution_ids":["https://openalex.org/I4210151833"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028596081","display_name":"David Planchard","orcid":"https://orcid.org/0000-0002-1565-8310","observed_orcids":["https://orcid.org/0000-0002-1565-8310"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]},{"id":"https://openalex.org/I4405269973","display_name":"Fondation Gustave Roussy","ror":"https://ror.org/05rfnt234","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4405269973"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"David Planchard","raw_affiliation_strings":["Medical Oncology Department, Thoracic Group, Gustave Roussy, Villejuif, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department, Thoracic Group, Gustave Roussy, Villejuif, France;","institution_ids":["https://openalex.org/I2801843802","https://openalex.org/I4405269973"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027610105","display_name":"L\u00fchua Wang","orcid":"https://orcid.org/0000-0002-5272-1681","observed_orcids":["https://orcid.org/0000-0002-5272-1681","https://orcid.org/0009-0005-8280-9018"]},"institutions":[{"id":"https://openalex.org/I200296433","display_name":"Chinese Academy of Medical Sciences & Peking Union Medical College","ror":"https://ror.org/02drdmm93","country_code":"CN","type":"education","lineage":["https://openalex.org/I200296433"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Luhua Wang","raw_affiliation_strings":["4National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen, China;","institution_ids":["https://openalex.org/I200296433"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020548160","display_name":"Alicia Cheong","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alicia Cheong","raw_affiliation_strings":["Celgene Europe Ltd, Uxbridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Europe Ltd, Uxbridge, United Kingdom;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108517536","display_name":"Huong Nguyen","orcid":"https://orcid.org/0009-0001-8693-4298","observed_orcids":["https://orcid.org/0009-0001-8693-4298"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marie Huong Nguyen","raw_affiliation_strings":["Celgene Corporation, Summit, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ;","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028259109","display_name":"Ruta J. Slepetis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruta Slepetis","raw_affiliation_strings":["Celgene Corporation, Summit, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ;","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063904421","display_name":"Everett E. Vokes","orcid":"https://orcid.org/0000-0002-8645-8068","observed_orcids":["https://orcid.org/0000-0002-8645-8068"]},"institutions":[{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Everett E. Vokes","raw_affiliation_strings":["University of Chicago Medical Center, Chicago, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago Medical Center, Chicago, IL;","institution_ids":["https://openalex.org/I4210087865"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"37","issue":"15_suppl","first_page":"TPS8574","last_page":"TPS8574"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.8970000147819519,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.8970000147819519,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.07810000330209732,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.011300000362098217,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tislelizumab","display_name":"tislelizumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/concurrent-chemoradiotherapy","display_name":"concurrent chemoradiotherapy","score":0.8479999899864197},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8309999704360962},{"id":"https://openalex.org/keywords/stage-iii-non-small-cell-lung-cancer","display_name":"stage III NSCLC","score":0.8859999775886536},{"id":"https://openalex.org/keywords/locally-advanced-unresectable-lung-cancer","display_name":"locally advanced unresectable lung cancer","score":0.8330000042915344},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.7739999890327454},{"id":"https://openalex.org/keywords/pd-l1-blockade","display_name":"PD-L1 blockade","score":0.6010000109672546},{"id":"https://openalex.org/keywords/radiotherapy-combined-with-immunotherapy","display_name":"radiotherapy combined with immunotherapy","score":0.7390000224113464},{"id":"https://openalex.org/keywords/consolidation-therapy","display_name":"consolidation therapy","score":0.5989999771118164},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9419999718666077},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.4819999933242798},{"id":"https://openalex.org/keywords/etoposide","display_name":"etoposide","score":0.9520000219345093},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.9900000095367432},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.9990000128746033},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.5860000252723694}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9068313837051392},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6313295364379883},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6215139627456665},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6192450523376465},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.546051025390625},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.49393659830093384},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.4836760461330414},{"id":"https://openalex.org/C2779177807","wikidata":"https://www.wikidata.org/wiki/Q3658562","display_name":"non-small cell lung cancer (NSCLC)","level":4,"score":0.46963927149772644},{"id":"https://openalex.org/C2778119113","wikidata":"https://www.wikidata.org/wiki/Q418817","display_name":"Etoposide","level":3,"score":0.4227531850337982},{"id":"https://openalex.org/C2778424827","wikidata":"https://www.wikidata.org/wiki/Q5090613","display_name":"Chemoradiotherapy","level":3,"score":0.41662928462028503},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.3743264675140381},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.34204810857772827},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3373395502567291},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2864387631416321},{"id":"https://openalex.org/C81729549","wikidata":"https://www.wikidata.org/wiki/Q4649475","display_name":"A549 cell","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2019.37.15_suppl.tps8574","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.tps8574","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.tps8574","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2939702267","https://openalex.org/W7210153678","https://openalex.org/W4307141900","https://openalex.org/W2947228307","https://openalex.org/W2598807078","https://openalex.org/W3088116761","https://openalex.org/W7211873640","https://openalex.org/W4415520148","https://openalex.org/W3031396542","https://openalex.org/W2947750888"],"abstract_inverted_index":{"TPS8574":[0],"Background:":[1],"cCRT":[2,33,97,117,164],"improves":[3],"survival":[4,23],"vs":[5,116,247,253],"RT":[6,122],"alone":[7,118],"and":[8,32,39,47,66,194,201,267,278],"is":[9,168,183,286],"a":[10,82,131,174,213,218,233],"global":[11],"standard":[12],"of":[13,68,91,134,144,162,216,220,239,271],"care":[14],"in":[15,49,81,98,126],"patients":[16],"(pts)":[17],"with":[18,96,209],"stage":[19,263,272],"III":[20,264,273],"NSCLC,":[21],"but":[22],"remains":[24],"poor":[25],"for":[26,207,235,241],"these":[27],"pts.":[28],"Combining":[29],"PD-1/PD-L1-targeting":[30],"immunotherapies":[31],"may":[34],"lead":[35],"to":[36,86,100,130,156,226,231,290],"synergistic":[37],"activity":[38,46],"improved":[40],"outcomes.":[41],"Tislelizumab":[42],"(anti\u2013PD-1)":[43],"demonstrated":[44],"clinical":[45,210],"tolerability":[48],"solid":[50],"tumors,":[51],"including":[52],"NSCLC.":[53],"This":[54],"phase":[55],"III,":[56],"randomized,":[57],"double-blind,":[58],"placebo-controlled":[59],"study":[60,84],"(RATIONALE":[61],"001)":[62],"will":[63,77,113,123,140,204],"evaluate":[64,87],"efficacy":[65],"safety":[67,153],"tislelizumab":[69,93,107,166],"+":[70,146,150,159,165],"cCRT.":[71],"Methods:":[72],"Pts":[73],"(N":[74],"\u2248":[75,228],"840)":[76],"be":[78,124,141,205],"randomized":[79],"1:1:1":[80],"3-arm":[83],"design":[85],"whether":[88],"the":[89,157,163],"timing":[90],"giving":[92,106],"earlier":[94],"upfront":[95],"addition":[99],"as":[101,108],"consolidation":[102,109],"(Arm":[103,111,119,245],"1)":[104],"or":[105,148,237,250],"only":[110],"2)":[112],"improve":[114],"outcomes":[115],"3;":[120],"Table).":[121],"given":[125],"2":[127,252],"Gy":[128,136],"fractions":[129],"target":[132],"dose":[133],"60":[135],"(30":[137],"fractions).":[138],"Chemotherapy":[139],"investigator\u2019s":[142],"choice":[143],"cisplatin":[145,158],"etoposide":[147,160],"carboplatin":[149],"paclitaxel.":[151],"A":[152],"analysis":[154],"specific":[155],"component":[161],"combination":[167],"planned.":[169],"All":[170],"sites":[171],"must":[172],"pass":[173],"radiation":[175],"quality":[176],"assurance":[177],"review":[178],"process.":[179],"The":[180],"primary":[181],"endpoint":[182],"PFS.":[184],"Secondary":[185],"endpoints":[186],"include":[187],"ORR,":[188],"OS,":[189],"OS":[190],"at":[191],"24":[192],"months,":[193],"safety.":[195],"As":[196],"an":[197],"exploratory":[198],"endpoint,":[199],"blood":[200],"tumor":[202],"biomarkers":[203],"assessed":[206],"correlations":[208],"benefit.":[211],"With":[212],"one-sided":[214],"\u03b1":[215],"1.25%,":[217],"total":[219],"580":[221],"PFS":[222],"events":[223],"are":[224,259],"required":[225,288],"allow":[227],"90%":[229],"power":[230],"detect":[232],"HR":[234],"progression":[236],"death":[238],"0.7":[240],"either":[242],"pairwise":[243],"comparison":[244],"1":[246],"Arm":[248,251,254],"3":[249],"3).":[255],"Key":[256],"eligibility":[257],"criteria":[258],"locally":[260],"advanced,":[261],"unresectable,":[262],"NSCLC;":[265],"FDG-PET":[266],"brain":[268],"imaging":[269],"confirmation":[270],"status;":[274],"no":[275],"prior":[276,289],"treatment;":[277],"ECOG":[279],"PS":[280],"\u2264":[281],"1.":[282],"PD-L1":[283],"expression":[284],"assessment":[285],"not":[287],"randomization.":[291],"EudraCT":[292],"number":[293],"2018-001132-22.":[294],"Clinical":[295],"trial":[296],"information:":[297],"NCT03745222.":[298],"[Table:":[299],"see":[300],"text]":[301]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":1}],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2019-06-07T00:00:00"}